Patents Represented by Attorney Exelixis, INC
  • Patent number: 7579473
    Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: August 25, 2009
    Assignee: Exelixis, Inc.
    Inventors: Lynne Canne Bannen, Diva Sze-Ming Chan, Timothy Patrick Forsyth, Richard George Khoury, James William Leahy, Morrisson B. Mac, Larry W. Mann, John M. Nuss, Jason Jevious Parks, Yong Wang, Wie Xu
  • Patent number: 7049088
    Abstract: Human PRMT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of PRMT are provided.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: May 23, 2006
    Assignee: Exelixis, INC
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Rolf Peter Ryseck, Lata Jayaraman, David K. Bol, Matthew Lorenzi
  • Patent number: 6927022
    Abstract: Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: August 9, 2005
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Roel P. Funke, Marcia Belvin, Danxi Li, Stephanie A. Robertson
  • Patent number: 6924117
    Abstract: Rhomboid Related Proteins (RRPs), involved in the EGFR signaling pathway, are provided. Transgenic, nonhuman mammals containing a transgene encoding an RRP polypeptide or a gene effecting the expression of an RRP polypeptide, along with methods of modulating the interaction of RRP proteins with their pathway members, and methods of screening for agents that modulate the interaction of an RRP polypeptide with an RRP binding target, such as RRP-specific antibodies and small molecules identified in high throughput screens, are also provided. Modulating agents identified using the methods of the invention can be used to specifically inhibit growth of tumor cells that overexpress an RRP protein.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: August 2, 2005
    Assignee: Exelixis, Inc.
    Inventors: Mario N. Lioubin, Lori Friedman, Marcia Belvin, Jeffery S. Larson, Changyou Chen, Stephanie A. Robertson, Wen Shi, Jocelyn Chan, Danxi Li
  • Patent number: 6509191
    Abstract: The present invention is directed to a novel plant phenotype, designated PAGODA (PGD), a nucleic acid sequence expressed in plants demonstrating the PGD phenotype and the corresponding amino acid sequence. Also provided are plant cells and plants that exhibit modified PGD expression.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: January 21, 2003
    Inventors: Alex Liu, Helena Mathews, Jill Van Winkle, Ry Wagner, Stanley R. Bates, Susan Bovee-Picciano